Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935966 | 0.93 | TGM2 (0.55) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL9825955 | 0.91 | TGM2 (0.46) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL9825089 | 0.90 | TGM2 (0.46) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL9826166 | 0.88 | TGM2 (0.61) | TGM2CYP1A2ITGB3ITGA2B | |
| SCHEMBL9825615 | 0.88 | TGM2 (0.44) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL4657328 | 0.87 | TGM2 (0.58) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL9825654 | 0.84 | TGM2 (0.62) | TGM2CYP1A2ITGB3ITGA2BMME | |
| SCHEMBL4597992 | 0.82 | TGM2 (0.56) | TGM2 | |
| SCHEMBL4598615 | 0.80 | TGM2 (0.51) | TGM2 | |
| SCHEMBL9825565 | 0.78 | TGM2 (0.47) | TGM2CYP1A2ITGB3ITGA2BMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | TGM2 16/4885CYP1A2 912/4885ITGB3 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.